ALISO VIEJO, Calif., July 08, 2025 (GLOBE NEWSWIRE) -- (NASDAQ: RXST) – RxSight, Inc., an ophthalmic medical device company dedicated to providing high-quality customized vision to patients following cataract surgery, today announced select preliminary financial results for the second quarter 2025 and revised full-year 2025 guidance. The Company will host a conference call on Tuesday, July 8, 2025, at 5:00 p.m. Eastern Time. Preliminary Second Quarter 2025 Results Preliminary second quarter 2025 revenue is ...

Core Insights - RxSight, Inc. is an ophthalmic medical device company focused on providing customized vision solutions for patients post-cataract surgery [3] - The company will participate in the Stifel Virtual Ophthalmology Forum on May 27, 2025, featuring a fireside chat with management [2] Company Overview - RxSight offers the RxSight® Light Adjustable Lens system, which includes the Light Adjustable Lens (LAL®/LAL+®) and the Light Delivery Device (LDD™), the first adjustable intraocular lens technology available commercially [3] - This technology allows for post-surgery adjustments, enabling personalized vision outcomes for cataract surgery patients [3] Event Participation - The management of RxSight is scheduled for a fireside chat at 10:30 a.m. Pacific Time / 1:30 p.m. Eastern Time on May 27, 2025 [2] - A live and archived webcast of the presentation will be accessible on the company's investor relations website [2]